ProCE Banner Activity

GALLIUM: Obinutuzumab- vs Rituximab-Based Immunochemotherapy in Patients With Untreated Follicular Lymphoma

Slideset Download
Conference Coverage
Obinutuzumab-based therapy reduced the risk of progression or death by 34% compared with rituximab-based therapy in patients with untreated follicular lymphoma.

Released: December 09, 2016

Expiration: December 08, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Seagen